S.876 - Human Cloning Ban and Stem Cell Research Protection Act of 2005109th Congress (2005-2006)
|Sponsor:||Sen. Hatch, Orrin G. [R-UT] (Introduced 04/21/2005)|
|Committees:||Senate - Judiciary|
|Latest Action:||04/21/2005 Read twice and referred to the Committee on the Judiciary. (text of measure as introduced: CR S4121-4122) (All Actions)|
This bill has the status Introduced
Here are the steps for Status of Legislation:
Summary: S.876 — 109th Congress (2005-2006)All Bill Information (Except Text)
Introduced in Senate (04/21/2005)
Human Cloning Ban and Stem Cell Research Protection Act of 2005 - Prohibits: (1) conducting or attempting to conduct human cloning; (2) shipping the product of nuclear transplantation in interstate or foreign commerce for the purpose of human cloning in the United States or elsewhere; or (3) exporting to a foreign country an unfertilized blastocyst if such country does not prohibit human cloning. Sets forth criminal and civil penalties for violations.
Requires the Comptroller General to report to the relevant congressional committees on: (1) actions taken to enforce such prohibitions; (2) actions of State attorneys general to enforce similar State laws; (3) coordination of Federal, State, and local enforcement; and (4) international laws relating to human cloning.
Amends the Public Health Service Act to require research involving nuclear transplantation to be conducted in accordance with applicable Federal regulations regarding the protection of human subjects and Institutional Review Boards. Prohibits: (1) a somatic cell nucleus from being transplanted into a human oocyte (egg) that has undergone or will undergo fertilization; (2) an unfertilized blastocyst from being maintained after more than 14 days from its first cell division, not counting storage times at temperatures less than zero degrees centigrade; (3) an oocyte from being used in nuclear transplantation research unless donated voluntarily with the donor's informed consent; (4) a human oocyte or unfertilized blastocyst from being acquired, received, or transferred for valuable consideration in interstate commerce; and (5) nuclear transplantation in a laboratory in which human oocytes are subject to assisted reproductive technology treatments or procedures. Sets forth civil penalties for violations.